Al-Kuraishy Hayder M, Sulaiman Ghassan M, Mohammed Hamdoon A, Saad Hebatallah M, Al-Gareeb Ali I, Albuhadily Ali K
Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
Department of Biotechnology, College of Applied Sciences, University of Technology, Baghdad, Iraq.
Inflammopharmacology. 2025 Jun 3. doi: 10.1007/s10787-025-01796-w.
Alzheimer's disease (AD) is the most common age-related neurodegenerative disease worldwide. The pathogenesis of AD is related to the progressive neuronal apoptosis due to the advanced accumulation of extracellular amyloid beta (Aβ) peptide and intracellular neurofibrillary tangles (NFTs), which are caused by hyperphosphorylation of tau protein. The accumulation of Aβ and NFTs in AD is affected by diverse signaling pathways, such as Janus tyrosine kinase (JAK) and signal transducer and activator of transcription (STAT), which are involved in the JAK/STAT signaling pathway. This signaling pathway controls cell proliferation, differentiation, and survival. The JAK/STAT signaling pathway plays a critical role in the development of neurodegeneration and neuroinflammation in AD. Also, suppressor of cytokine signaling (SOCS), a negative regulator of the JAK/STAT signaling pathway, is also affected in AD. Nevertheless, the fundamental mechanism for the dysregulation of the JAK/STAT3/SOCS signaling pathway in AD is not completely explained. Henceforth, this review aims to explain and discuss the precise role of the JAK/STAT3/SOCS signaling pathway in AD and how targeting of this pathway could be effective in the management of AD.
阿尔茨海默病(AD)是全球最常见的与年龄相关的神经退行性疾病。AD的发病机制与细胞外淀粉样β(Aβ)肽的过度积累和细胞内神经原纤维缠结(NFTs)导致的神经元进行性凋亡有关,而神经原纤维缠结是由tau蛋白的过度磷酸化引起的。AD中Aβ和NFTs的积累受多种信号通路影响,如参与JAK/STAT信号通路的Janus酪氨酸激酶(JAK)和信号转导及转录激活因子(STAT)。该信号通路控制细胞增殖、分化和存活。JAK/STAT信号通路在AD的神经退行性变和神经炎症发展中起关键作用。此外,细胞因子信号抑制因子(SOCS)作为JAK/STAT信号通路的负调节因子,在AD中也受到影响。然而,AD中JAK/STAT3/SOCS信号通路失调的基本机制尚未完全阐明。因此,本综述旨在解释和讨论JAK/STAT3/SOCS信号通路在AD中的精确作用,以及靶向该通路如何有效地治疗AD。
Inflammopharmacology. 2025-6-3
Indian J Ophthalmol. 2025-6-1
Autophagy Rep. 2025-2-13
Behav Brain Res. 2025-5-28
Arch Dermatol Res. 2024-12-12
Int Immunopharmacol. 2024-11-15
Eur J Pharmacol. 2024-5-5